New York Oncology Hematology, P.C.

Clifton Park, New York 12065

0 studies enrolling now · 8 studies all time

What they study most

BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer, Breast Neoplasms, Cancer, Carcinoma, Renal Cell, Colorectal Cancer (CRC), KEAP1 Gene Mutation, Lung Cancer, Melanoma, NFE2L2 Gene Mutation, NRF2 Gene Mutation

Studies at this site

• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors — Completed
• An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib — Running, not enrolling
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) — Completed
• The Circulating Cell-free Genome Atlas Study — Status unconfirmed
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) — Completed
• KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC — Stopped early
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed